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Epicardial marker motion was measured in 14 pa- 
tients before flecainide administration, immediately 
after an intravenous dose of 2 mg/kg over 15 min- 
utes (maximum’ 150 mg) and 15 minutes thereafter. 
Platinum epicardial markers had been implanted 
more than 4 years earlier at the time of coronary 
artery bypass grafting. Maximal and minimal marker 
separation (Lmax and Lmin) during the cardiac cy- 
cle were measured and regional shortening fraction 
(Lmax - Lmin)/Lmax) was determined as a per: 
centage. After intravenous flecainide, a significant 
increase in end-diastolic (immediately after 2.8%; 
after 15 minutes 2.1% ) and end-systolic (3.8 % 
and 3.2% ) regional dimensions was observed, to- 
gether with a decrease in regional myocardial short- 
ening (9.3% and 9.0%). One week later, after a 
single oral dose of 200 mg of flecainide, Lmax and 
Lmin had increased 2.4 % and 2.7 % , while region- 
al myocardial shortening did not differ significantly, 
from baseline values. In 19 patients measurements 
were repeated after 8 weeks of chronic oral treat- 
ment with 300 mg/day. Despite plasma flecainide 
levels similar to those after intravenous administra- 
tion, no significant changes.in’end-diastolic and 
end-systolic dimensions or regional shortening frac- 
tion were observed. Thus, acute intravenous or oral 
flecainide administration increases regional end-dia- 
stolic and end-systolic dimensions, but only intrave- 
nous administration decreases regional shortening 
fraction. Values during chronic administration indi- 
cate that regional myocardial function is more af- 
fected at the time of rising or acutely changing fle- 
cainide plasma levels than when stable plasma 
levels are achieved. 
(Am J Cardiol 1988;58:470-475) 
F lecainide acetate, an antiarrhythmic agent that 
slows atrial, nodal and ventricular conduction and in- 
creases atria1 and ventricular refractoriness,1-4 is ef- 
fective in suppressing ventricular arrhythmias and 
reentrant tachycardias related to anomalous atrioven- 
tricular pathways4-l2 
A myocardial depressant effect after intravenous 
administration of flecainide in humans has been re- 
ported,13-l5 whereas echocardiographic measures of 
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left ventricular function measured during oral treat- 
ment usually did not change.5-7J6 However,, clinical 
heart failure during chronic oral treatment has been 
reported to develop or to become aggravated in ap- 
proximately 4% of patientsI 
We evaluated the effect of acute intravenous, acute 
oral and chronic oral flecainide administrationon left 
ventricular regional wall motion, as measured from 
implanted epicardial markers, in the same patients 
with coronary artery disease who had previously un- 
dergone coronary artery bypass surgery (CABG).17 
Methods 
Fourteen men, aged 50 to 63 years [mean 55) partic- 
ipated in the study. All had undergone CABG 4 to 7 
years earlier. Five patients presented with chronic 
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TABLE I Patients 
Pt Age W Previous MI AP 
Marker Pairs 
EF 
NYHA EDV (ml/m*) (%) Hypokinetic Normokinetic 
1 54 + + 2 
2 53 - 1 
3 62 + + 2 
4 63 + t 2 
5 52 t + 2 
6 60 + 2 
7 51 - - 1 
8 51 t - 1 
9 62 t - 1 
10 57 + + 2 
11 50 + t 1 
12 52 + - 1 
13 53 t - 1 
14 56 t - 1 
62 68 2 1 
85 64 1 1 
68 65 1 1 
54 74 1 2 
120 30 2 1 
83 39 1 2 
79 56 1 1 
64 - 0 1 
115 32 3 0 
78 49 1 1 
67 64 1 1 
113 56 1 1 
74 64 1 2 
98 46 1 2 
AP = anaina oectoris: EDV = end-diastolic volume: EF = ejection fraction; MI = myocardial infarction; NYHA = 
New York Heart’Association class. 
ventricular arrhythmias and 9 had no significant ven- 
tric,ular arrhythmias. All gave informed consent to par- 
ticipate in this study. At the time of CABG 12 patients 
had 3-vessel ahd 2 had Z-vessel coronary artery dis- 
ease (Table I]. 
A complete medical history as well as a routine 
physical examination were obtained from all patients 
on entering the study. 
Heart rate, blood pressure, biplane x-ray cinefilm 
of radiopaque marker motion, electrocardiographic 
intervals and plasma flecaitiide levels were measured. 
These variables were measured with the patient in the 
supine position in the catheterization laboratory and 
were repeated 6 times. During the first visit, indwell- 
ing intravenous catheters were inserted at least half an 
hour before values were measured. After baseline 
measurements were made, flecainide was adminis- 
tered intravenously over 15 minutes at a dose of 2 
mg/kg (maximum 150 mg). Measurements were re- 
peated immediately thereafter and 15 minutes later; 
blood samples were obtained at the same times. One 
week later, measurements were taken 2 to 4 hours 
(mean 2 haurS55 minutes] after an oral flecainide dose 
of 201) mg. Thereafter, flecainide, 150 mg 2 times daily, 
was administered during a 6-week period. Ten pa- 
tients participated in this chronic treatment period. At 
the end of this period the measurements were repeat- 
ed 6 to 10 hours (mean 8 hours 20 minutes] after the 
last oral dose. Flecainide therapy was then discontin- 
ued and final measurements were recorded 1 week 
thereafter. 
Plasma flecainide levels were determined using a 
gas-liquid chromatpgraphic method; measurements 
were conducted at the Department of Pharmacology of 
the University of Groningen. 
Regional wall motion: Regional myocardial motion 
was determined from radiopaque markers implanted 
during CABG on the left ventricular epicardium in 
each bypassed region in pairs approximately 2 cm 
apart and Iocated 0 to 3 cm distal to the coronary anas- 
tomosis (Fig. 1). This technique has been described 
previously.17-21 Three consecutive beats were record- 
ed on synchronized biplane cinefilms (50 frames/s) in 
30’ right anterior oblique and 60’ left anterior oblique 
projections. Correction for x-ray and optical distortion 
was performed to give true anatomic dimensions. Be- 
cause the biplane technique was used, small errors 
due to lateral and transverse rotation were eliminated. 
The position of the roentgen apparatus wa8 not 
changed during sequential recordings. Separation of 
marker pairs was plotted with regard to the onset of 
electrical activity. Lmax and Lmin were defined as 
maximal and minimal marker separation. The short- 
ening fraction between these 2 points was calculated 
as (Lmax - Lmin)/Lmax and was expressed as a 
percentage. 
Because marker filming at each measurement was 
performed without repositioning the equipment or the 
patient, the measurement error is primarily due to 
beatlto-beat variability, which is defined as the pooled 
standard deviation in Lmax divided by Lmax and ex- 
pressed as a percentage. For biplane recording this 
averaged 0.66%. Given a marker separation of 2 cm 
and averaging the results of 3 beats, the 95% con- 
fidence limit of the mean is less than 0.13 mm. Mea- 
surement error and observer variability have been 
reported.17 
Regional myocardial shortening was considered 
normal if it was more than lo%, hypokinetic if be- 
tween 5 and 10% and akinetic if less than 5%.17 
Results 
Acute intravenous administration: Measurements 
were performed in 14 patients with 34 platinum mark- 
er pairs implanted. A mean flecainide dose of 139.6 mg 
(range 120 to 150) was administered intravenously over 
15 minutes. Except for slight buccal paresthesias in 1 
patient, no adverse effects occurred. No significant 
changes in heart rate or blood pressure were seen. 
Plasma flecainide levels immediately after infusion 
and 15 minutes later were 541 f 157 and 285 f 62 ng/ 
ml, respectively [n = 12). 
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TABLE II Regional Left Ventricular Wall Motion Measurements After Intravenous and Oral Flecainlde 
After 15 Min. After 
Control i.v. FI. p Value’ i.v. FI. p Value” 
Lmax (cm) 2.86 f 0.98 2.94 f 0.99 0.61 I 2.92 f 0.97 0.031 
Lmin (cm) 2.53 f 0.90 2.62 f 0.91 0.0007 2.61 f 0.89 0.0025 
SF (%) (n = 34) ii.74 f 4.89 10.65 f 4.32 0.0019 10.68 f 4.59 0.0002 
SF hypokinetic -I- akinetic 7.74 f 1.92 7.29 f 2.50 NS 7.07 f 2.34 NS 
segments (% ) (n = 17) 
SF normokinetic 15.75 f 3.47 14.01 f 2.89 0.0013 14.31 f 3.18 0.0006 
segments (% ) (n = 17) 
After Oral FI. 
2.93 f 0.98 
2.60 f 0.86 
11.09 f 4.68 
7.46 f 2.84 







l Student paired t test with regard to control. 
FI. = flecainide; NS = not significant; SF = shortening fraction. 
Electrocardiographic intervals: PR interval, QRS 
duration and QT interval increased significantly, by 
2470, 23% and 8%, after flecainide infusion. These 
intervals remained prolonged by 19%, 15% and 7% 15 
minutes later (p <0.05). 
fraction was observed after flecainide in normokinetic 
segments but not in hypokinetic segments (Table II). 
Heart rate before, immediately after and 15 min- 
utes later was 70,71 and 70 beats/min (difference not 
significant]. 
Regional wall motion: Both Lmax and Lmin in- 
creased significantly after intravenous flecainide ad- 
ministration (Table II], 
Shortening fraction decreased significantly, since 
the increase in Lmin was more pronounced than the 
increase in Lmax. Shortening fraction was 11.74 f 
4.89% before flecainide and decreased to 10.65 f 
4.32% after infusion and 10.68 f 4.59% 15 minutes 
later (Table II). 
Oral administration: After a single oral dose of 200 
mg: Plasma flecainide level determined 2 to 4 hours 
(mean 2 hours 75 minutes) after a single oral dose of 
200 mg was 262 f 73 rig/ml (n = 12). This level was 
significantly lower than that immediately after intra- 
venous infusion of flecainide, but not different from 
the level 15 minutes after intravenous infusion. QRS 
interval did not differ from the baseline level, whereas 
PR and QT intervals increased by 11% and 570, re- 
spectively (p <0.05]. 
Regional wall motion: Lmax and Lmin were 2.93 f 
0.98 and 2.60 f 0.88 cm. Both values were significantly 
different from baseline values. Shortening fraction 
was 11.09 f 4.68%, not significantly different from the 
baseline value [Table II). 
Regional myocardial wall motion was normokinet- Lmax after a single oral dose did not differ from 
ic in 17 segments, hypokinetic in 16 and akinetic in 1 Lmax after intravenous administration of flecainide, 
segment (Table I). A significant decrease in shortening whereas the increase in Lmin after oral flecainide 





im ediately during chronic 
after acute after acute after a sin le treotment wlth 
intravenous intravenous oral dose o I Flecainide 
Flecainide Flecainide Flecoinlde 
FIGURE 1. a, regional myocardlal shortening was determined from radiopaque markers Implanted durlng surgery on the left ventricular 
epicardium in each bypassed region, in pairs 2 cm apart and located from 0 to 3 cm distal to the coronary anastomosls.17 b, clneradiogram 
of 1 marker pair of bars and 1 marker pair of beads in 60’ left anterior oblique projection. c, marker pair shortening for a normal contraction. 
Separation of the marker pair is plotted with regard to the onset of electrical activity (Q wave of the electrocaidlogram [ECG]). Shortening 
fraction (SF) is ditermlned beat by beat and averaged over 3 beats. Lmax and Lmln = maximal and minimal marker separation. d, motion 
pattern of 1 marker pair in 1 patient during 3 consecutive beats before flecainide infusion, Immediately after Infusion, 15 minutes after 
infusion, after a single oral dose and during chronic treatment. After infusion of flecalnide and after a single oral dose Lmax and Lmln 
increase. This Increase is less during chronic treatment. Calculated shortening fraction before flecainlde was 6.15%, immediately after 
and 15 minutes after Intravenous Infusion 6.14% and 6.31% respectively, after a single oral dose 7.53% and during chronic treatment 
6.06%. 
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tended to be less pronounced than after intravenous 
administration (p = 0.06). 
During chrpnic oral treatment: Measurements dur- 
ing chronic oral treatment with 300 mg/day of flecai- 
nide were available,in 10 patients with 26 marker pairs 
implanted. One patient stopped therapy because of 
gtistrointestinal coniplaints. Another patient was with- 
drawn from the study after an episgde of unexplained 
syticope; the plasma flecainide level shortly thereafter 
was 350 rig/ml. On the electrocardiogram first-degree 
atrioventricular block was present without significant 
ventricular arrhythmias. The patient was readmitted a 
few mqnths later to the neurologic department be- 
cause of amaurosis fugax, and right carotid artery ste- 
nosis was diagnosed. Two patients refused chronic ad- 
ministration of the drug. The.plasma flecainide level 
during chronic treatment determined 6 to 10 hours 
after the last flecainide dose (mean 8 hours 20 minutes) 
was 449 f 132 rig/ml (n = 10). This level was higher 
than that aftejr a single oral dose (p <O.OOS) and 15 
minutes after intravenous infusion (p X0.01), but was 
not significantly different from the level immediately 
after intravenous infusion. 
During chronic flecainide administration QRS du- 
ration and QT interval were not significantly different 
from baseline values, whereas PR interval increased 
by 12% (p <0.05). 
Regional wall motion: Lmax arid Lmin were 2.93 f 
1.05 and 2.58 f 0.95 cm, respectively. Neither value 
was significantly different from baseline 12.89 f 1.08 
and 2.53 f 0.99 cm, n = 26). Shortening fraction was 
12.0 f 4.7% (baseline 12.5 f 4.870, p <0.2) and re- 
mained unchanged. 
Lmax and Lmin were significantly smaller during 
chronic treatment than after intravenous injection or 
after a single oral flecainide dose. Shortening fraction 
dyring chronic treatment w&s significantly greater 
than immediately after an intravenous dose of flecai- 
&de (12.0 f 4.7% vs 11.2 f 4.07’0, p <O.Ol) (Fig. 2). 
Discussion 
Regional myocaidial function, particularly in pa- 
tients with cororiary artery disease, has been assessed 
by 2-dimensional and M-mode echocardiography, by 
radiopaque contrast and by radionuclide ventriculog- 
raphy. The last technique was not considered for the 
present study because repeated measurements, and 
therefore repeated exposure to ionizing radiation, are 
required. N&G of these dethods accurately assess 
transverse epicardial shortening. Our method pro- 
vides accurate, specific and heretofore unavailable in- 
formation on regional epicardial shortening and di- 
mensions.17-21 We conservatively estimate that the 
overall margin of error is less than 0.66% in shortening 
fraction and less than 0.13 mm for a maximal marker 
separatibn (Lmax) of 20 mm. In this study, we chose not 
to run a parallel control group because we showed in a 
previous study that measurements of regional epicar- 
dial shortening remain stable during a 6-month period 
in patients without intercurrent cardiac events.19 
Therefore, we reasoned that each patient could serve 
as his own control. The clinical value of new antiar- 
rhythmic agents such as flecainide would be enhanced 
if there were only minimal depression of left ventricu- 
lar function, so that patients with impaired cardiac 
function, who often present with severe ventricular 
arrhythmias, could also b,enefit.22 
The hemodynamic effect of flecainide after acute 
intravenous administration has been studied previous- 
ly, with similar results. 13-15 Parameters related to myo- 
cardial contractility, such as peak positive dP!dt and 
Vmax, decrease after intravenous administration of 2 
mg/kg of flecainide. l4 Increases in pulmonary wedge 
pressure and left* ventricular end-diastolic pressure 
have been observed, together with decreases in cardi- 
ac index (7 to l2%] and left ventricular ejection frac- 
tion (7 to 16!70).~~-~! 
The hemodynamic effects of acute and chronic oral 
administration of antiarrhythmic agents may be dis- 
similar from those observed dtiring acute intravenous 
administration. In the present study we compared the 
effects of an acute oral dose of flecainide and of chroti- 
ic flecainide administration with the effect df an intra- 
venous dose in the same patients. 
Immediately after intravenous administration both 
Lmax and Lmin increased and despite lower plasma 
flecainide levels, similar, increases were observed 15 
minutes later. In rats, cardiac tissue levels of flecainide 
have been reported to be ll- to l&fold higher than 
plasma flecainide levels, but elimination kinetics from 
the heart are similar to plasma elimination kinetics.23 
Cardiac tissue levels and elimination kinetics from the 
heart in humans are unknown. It might be hypothe- 
sized that flecainide elimination from the heart is 
slower in man, resulting in persistent hemodynamic 
% 
I 
Effect of flecainide on shortening fraction after intravenous 
injection, after acute oral and during chronic oral administra- 
tion (n-10) 
***p<o.o05 
(vs. before flecainide) 
00 p<o.o1 
0 pco.05 
(vs. after I.V. dose) 
before after 15’ after after durinb 
I.V. I.V. oral chronic 
dose dose dose treatment 
FIGURE 2. Effect of flecainlde on regional wall shortening fraction 
(SF) in the 10 patients who received chronic treatment. The results 
after intravenous injection or acute oral administration in this large 
subgroup (n = lo,26 marker pairs) are similar to those of the whole 
group (n = 14,34 marker pairs). Values are mean f standard error 
of the mean. 
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changes despite lower plasma flecainide levels. The 
preseht study shows an increase in systdlic and diastol- 
ic regional dimensions after intravenous flecainide, 
and since the increase in end-systolic regional dimen- 
sions is more pronounced, a decrease in regional 
shortening fraction occurred. ‘l?he changes may be re- 
lated t6 the increase in end-systolic volume after fle- 
cainide administration observed by Legrand et a113 
and the decrease in left ventricular ejection fraction 
observed by Legrand et alI3 and Josephson et al-l5 We 
have shown that regional myodardial shortening is 
not more impaired in hypokinetic segments than in 
normokinetic segments after intravenous flecainide 
administration. 
During chronic oral flecaihide treatment, investiga- 
tors have evaluated echocardiographic measures of 
left ventricular function. No changes in ejection f?ac- 
tion and fractional shortening were observed.5-7 
Hodges et all6 observed sniall increases in preejection 
period, preejection period/left ventticular ejection 
time ratio and left ventricular end-systdlic volume, to- 
gether with decreases in velocity of contractile shdrt- 
ening and left ventricular ejectjon fraction. That 
chronic flecainide administration can have a myocar- 
dial depressant effect is further emphasized by the 
observation15 that heart failure develops or was aggra- 
vated in 4% of 373 patients given flecainide to control 
ventricular tachyarrhythmias. 
We, measured regional wall motion after an oral 
dose of 200 mg at the time of expected maximal blood 
plasma levelsBz4 We did see changes in systolic and 
diastolic regional dime&ions after a single oral dose. 
Shortening fraction did nbt cl$nge significantly be- 
caus& both ,Lmax and Lmih increased in parallel, re- 
sulting in little net change c$ the Quantity Lmax-L&i. 
During chronic oral treatment with 300 kg/day of fle- 
cainide 6 weeks after starting therapy, no significant 
changes in epicardial regional diinensions and short- 
ening fraction were observed. Although the plasma 
flecainide level was not significantly different from 
that immediately after intravenous infusion, systolic 
regional dimensions were $maller and shor@ing 
fraction during chronic treatment Miss significantly 
higher. Despite higher plasma 1evels;regional dimen- 
sions were smaller during chronic oral trti&tment than 
after a single oral dose. These findings indicate that 
regional myocardial fuhction @pears to,be more af- 
fected,at he time of risidg or acutely changing plasma 
flecainide levels than wheti stabilized plasina levels 
are achieved. 
Some investigators have reported a sliiht increase 
in systemic vascular resistahce after intravenous fie- 
caiilide.13*14 As a consequence, an impaired emptying 
of the heart could be expected, attended by an in- 
crease in eird-systolic and end-diastblic dimensions. 
We did not invasively measure systemic vascular re- 
sistance; howevek, systemic blood pressure did not 
change significantly. The inctease in end-systolic and 
end-diastolic dimensions after intravenous adminis- 
tration and after a single oral dose can best be ex- 
plained by a direct negative inotropic effect of flecai- 
nide, as shown in both experimental and human 
clinical sttidies.13-16 
Regional myocardial shortening decreases after in- 
travenous flecainide adininistration bui appeats not to 
be niore impaired in hypokinetic than in hormokinetic 
wall segments. Fuithermorb, during chroiiic adminis- 
tration tind despite similar plasma flecainide levels, 
the effect on regional wall motion .i$ less pronounced 
than after intravenous administratibn. 
In conclusion,, flecainide plioduces a negative irio- 
tropic effect in humans that prohibits its use in pati,ents 
with severe heart failure, but it is not so great an effect 
to present serious problems in patients tiith a merely 
subnormal function. 
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